{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:18Z","timestamp":1758970818407,"version":"3.40.5"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.thromres.2018.08.008","type":"journal-article","created":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T14:05:51Z","timestamp":1534341951000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients"],"prefix":"10.1016","volume":"170","author":[{"given":"Hugo","family":"ten Cate","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthonie W.A.","family":"Lensing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1006-6420","authenticated-orcid":false,"given":"Saskia","family":"Middeldorp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Kubitza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothey","family":"Brighton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary E.","family":"Raskob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Prandoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Gebel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin H.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2018.08.008_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.thromres.2018.08.008_bb0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.thromres.2018.08.008_bb0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-013-1029-2","article-title":"A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban","volume":"38","author":"Kreutz","year":"2014","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2018.08.008_bb0020","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Einstein-DVT-Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.08.008_bb0025","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Einstein-PE-Investigators","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.08.008_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2018.08.008_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1477-9560-11-13","article-title":"Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2018.08.008_bb0040","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.08.008_bb0045","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"Prins","year":"2014","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.thromres.2018.08.008_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-9560-12-25","article-title":"Rivaroxaban versus enoxaparin\/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment","volume":"12","author":"Bauersachs","year":"2014","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2018.08.008_bb0055","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamainternmed.2014.946","article-title":"Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin","volume":"174","author":"Davidson","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.thromres.2018.08.008_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-11-11","article-title":"Laboratory assessment of rivaroxaban: a review","volume":"11","author":"Samama","year":"2013","journal-title":"Thromb. J."},{"key":"10.1016\/j.thromres.2018.08.008_bb0065","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.08.008_bb0070","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818304560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818304560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:10:33Z","timestamp":1589933433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818304560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":14,"alternative-id":["S0049384818304560"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.08.008","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}